Research Article

You have full text access to this OnlineOpen article

Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: A multicenter randomized, double-blind, placebo-controlled trial

  1. Deh-Ming Chang1,*,
  2. Joung-Liang Lan2,
  3. Hsiao-Yi Lin3,
  4. Shue-Fen Luo4

Article first published online: 8 NOV 2002

DOI: 10.1002/art.10615

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 46, Issue 11, pages 2924–2927, November 2002

Additional Information

How to Cite

Chang, D.-M., Lan, J.-L., Lin, H.-Y. and Luo, S.-F. (2002), Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: A multicenter randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism, 46: 2924–2927. doi: 10.1002/art.10615

Author Information

  1. 1

    Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China

  2. 2

    Veteran's General Hospital, Taichung, Taiwan, Republic of China

  3. 3

    Veteran's General Hospital, Taipei, Taiwan, Republic of China

  4. 4

    Chang-Gung Memorial Hospital, Taipei, Taiwan, Republic of China

*Tri-Service General Hospital, 325 Cheng-Kung Road, Section 2, Neihu 114, Taipei, Taiwan, Republic of China

Publication History

  1. Issue published online: 8 NOV 2002
  2. Article first published online: 8 NOV 2002
  3. Manuscript Accepted: 26 JUL 2002
  4. Manuscript Received: 6 FEB 2002

Funded by

  • Genelabs Biotechnology Company, Ltd.
  • National Science Council. Grant Number: NSC90-2314-B-016-069

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (54K)

REFERENCES

  • 1
    Schmidt M, Kreutz M, Loffler G, Scholmerich J, Straub RH. Conversion of dehydroepiandrosterone to downstream steroid hormones in macrophages. J Endocrinol 2000; 164: 161–9.
  • 2
    Lahita RG, Bradlow HL, Ginzler E, Pang S, New M. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987; 30: 241–8.
    Direct Link:
  • 3
    Straub RH, Scholmerich J, Zietz B. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases: substitutes of adrenal and sex hormones. Z Rheumatol 2000; 59Suppl 2: II/108–18.
  • 4
    Lucas JA, Ahmed SA, Casey ML, MacDonald PC. Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone. J Clin Invest 1985; 75: 2091–93.
  • 5
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7.
    Direct Link:
  • 6
    Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107–18.
    Direct Link:
  • 7
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630–40.
    Direct Link:
  • 8
    Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999; 8: 685–91.
  • 9
    Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol 1991; 147: 117–23.
  • 10
    Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Scholmerich J, et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998; 83: 2012–17.
  • 11
    Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2002; 46: 1820–9.
    Direct Link:
  • 12
    Mease PJ, Merrill JT, Lahita RG, Petri MA, Ginzler EM, Katz RS, et al. GL701 (prasterone, dehydroepiandrosterone) improves systemic lupus erythematosus [abstract]. Arthritis Rheum 2000; 43Suppl 9: S271.
  • 13
    Zhao YX, Andoh A, Shimada M, Takaya H, Hata K, Fujiyama Y, et al. Secretion of complement components of the alternative pathway (C3 and factor B) by the human alveolar type II epithelial cell line A549. Int J Mol Med 2000; 5: 415–9.
  • 14
    Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus: results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995; 38: 1826–31.
    Direct Link:
View Full Article (HTML) Get PDF (54K)